On Friday, President Trump held a live press even where he announced nine more participants for TrumpRx.¹

What companies joined TrumpRx?

The President was joined at the event by leaders from each of the companies, which included:

• Amgen
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Genentech
• Gilead
• GSK
• Merck
• Novartis
• Sanofi

During the briefing, President Trump also said that he had reached agreements with leaders from countries in Europe to ensure that drug prices in those countries matched prices in the United States. According to the President, he used tariffs as leverage in these negotiations.

Throughout the course of the year, President Trump has broadly used the threat of tariffs as a negotiating tactic. Earlier this year, he suggested that he may place 200% tariffs on pharmaceuticals. However, that threat was related to domestic manufacturing concerns and he appears to have shifted course and started making deals directly with pharma companies.

As an example, he said that if a drug cost $10 in the European country and $130 in the United States, it would cost $20 in both countries. The President also claimed that drug prices in the United States would be lowest in the developed world.

All future drug releases from these companies will also be available at MFN pricing through TrumpRx.

With this announcement, 14 of the 17 companies previously called out by the President for drug prices have announced deals with the administration to offer discounted medication on TrumpRx. The government-run website will launch sometime in 2026.

Earlier this year, the President issued an executive order demanding the pharmaceutical companies treat the United States as a most-favored-nation and offer medication as-low-as-or-lower than other regions.

In a post announcing the order, President Trump wrote, “For many years the World has wondered why Prescription Drugs and Pharmaceuticals in the United States of America were so much higher in price than they were in any other nation, sometimes being to ten more expensive than the same drug, manufactured in the exact same laboratory or plant, by the same company?”

In late-July, the President publicly published letters to major pharmaceutical companies, calling them out for not meeting the requirements of his executive order. In the letter, he wrote, “Make no mistake: a collaborative effort towards achieving global pricing parity would be the most effective path for companies, the government, and American patients. But if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued drug pricing practices.”

During today’s press event, President Trump suggested that the remaining three companies had also worked out deals with his administration and would be announcing them shortly.

In addition, Bristol Meyers Squibb announced an agreement with the US government to provide the blood thinner Eliquis for free for members of Medicaid.²

In a press release on the company’s website, Bristol Meyer’s Squibb chief executive officer and board chair Christopher Boerner, PhD, said, “We are taking direct action to improve the lives of millions of Americans, ensuring our nation’s most vulnerable have access to this critical medicine at no cost. Today’s agreement builds on BMS’s efforts to improve affordability, increase transparency and continue to invest in America, where we have an over 165-year history of discovering and developing life-changing medicines.”

Sources

1. WATCH LIVE: Trump expected to make announcement about lowering drug prices. PBS. December 19, 2025. https://www.pbs.org/newshour/health/watch-live-trump-expected-to-make-announcement-about-lowering-drug-prices
2. Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans. Bristol Myers Squibb. December 19, 2025. https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Announces-Agreement-with-U-S--Government-to-Improve-Affordability-and-Access-to-Critical-Medicines-for-Americans/default.aspx